Expression of c-Kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin

Journal of the Chinese Medical Association

Volumn 69, Issue 2, 2006, Pages 74-79

  Kung, Sung Pao ^a,b   Lee, Chen Hsen ^a,b   Yang, An Hang ^a,b   Chi, Chin Wen ^a,b   Tseng, Ling Ming ^a,b   Wu, Chew Wen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

C Kit; Flk 1; Flk 2; Thyroid tumors

Indexed keywords

FLK 2 RECEPTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLICULAR CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NODULAR GOITER; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; THYROID ADENOMA; THYROID CANCER; THYROID CARCINOMA; THYROID TUMOR; THYROIDECTOMY;

EID: 33644553842     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70117-0     Document Type: Article

References (21)

1. Risau W. Mechanisms of angiogenesis. Nature 1997;386: 671-4.
2. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475-80.
3. Patel A, Fenton C, Ramirez B, Dinauer CA, Tuttle RM, Nikiforov YE. Gary FL. Tyrosine kinase expression is increased in papillary thyroid carcinoma of children and young adults. Front Biosci 2000;5:1-9.
4. Thushanov S, Bronstein M, Adelaide J, Jussila L, Tchipysheva T, Jacquernier J, Stavrovskaya A, et al. VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer 2000; 86:47-52.
5. Fellmer PT, Sato K, Tanaka B, Okamoto T, Kato Y, Kobayashi M, Shibuya M, et al. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 1999;126:1056-61.
6. Bounone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-76.
7. Kebebew E, Wong MG, Siperstein AE, Duh QY, Clark OH. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated fiinction. J Clin Endocrinol Metab 1999;84:2840-7.
8. Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T, Shibuya M. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Patbol 1999;30: 891-7.
9. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999;161:41-9.
10. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metabol 1997;82: 3741-7.
11. Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Stibano S, De Rosa G, et al. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogcne 1999;18:4860-9.
12. Scarpino S, D'Alena FC, Di Napoli A, Ballarini F, Prat M, Ruco LP. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumor agiogenesis. J Pathol 2003;199:243-50.
13. Friguglietti CU, Mello ES, Castro IV, Filho GB, Alves VA. Metalloproteinase-9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. Head Neck 2000;22:373-9.
14. Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE. Human CD34+ hematopoietic stem cells capable of multifineage engrafting NOD/SCID mice express Flt3: distinct Flt3 and c-Kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003;102:881-6.
15. Takakura N, Watanabe Tsuenobu S, Yamada Y, Noda T, Ito Y Satake M, Suda T. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000;102:199-209.
16. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci USA 2001;98:14541-6.
17. Teller S, Kramer D, Bohmer SA, Tse KF, Small D, Mahboobi S, Wallrapp C, et al. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 2002;16:1528-34.
18. Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, et al. Cellular and molecular characterization of the role of the Flk-3/Flt-3 receptor tyrosine kinase in hematopoictic stem cells. Blood 1994;84:2422-30.
19. Kavantzas N, Tseleni-Balafouta S, Davaris P. Computerized nuclear morphometry and quantitation of angiogenesis in thyroid neoplasms. J Exp Clin Cancer Res 2002;21:247-54.
20. Winter WE 3rd, Seidman JD, Krivak TC, Chauhan S, Carlsan JW, Rose GS, Birrer MJ. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of uterine corpus. Gynecol Oncol 2003;91:3-8.
21. Krams M, Parwaresch R, Sipos B, Heidorn K, Harms D, Rudolph P. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene 2004;23:588-95.